Report: Monoclonal antibodies for dementia lack clear benefits, show risks
By
Kristen Fischer
Jan 23, 2024
Even though amyloid-reducing monoclonal antibodies (MABs) are on the market and some research shows they may treat Alzheimer’s disease and dementia, a new research review found there aren’t clear benefits...
Alzheimer’s drug donanemab finds late-stage trial success, safety concerns
By
Alicia Lasek
May 04, 2023
The experimental drug donanemab appears to halt the progression of Alzheimer’s disease and slow certain measures of clinical decline, new trial data show.
Also in the News for Tuesday, April 25
By
Kimberly Marselas
Apr 25, 2023
Budget proposal offers big money for nursing homes, elder care in Ohio … Louisiana legislators consider weakening brand new nursing home disaster plan rule … Small and rural providers continue to lag...
Patient advocates decry CMS decision on Alzheimer’s drug coverage
By
Alicia Lasek
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.
Also in the News for Wednesday, Jan. 4
By
Kimberly Marselas
Jan 04, 2023
COVID hospitalizations approach last summer’s high, but flu and RSV cases waning … NC nursing home to pay $126K after storm-related staff shortages, two patient deaths … FDA decision on experimental...
On eve of Alzheimer’s drug decision, Congress critiques FDA for Aduhelm review failures
By
Alicia Lasek
Jan 03, 2023
An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...
Depression drug eases Alzheimer’s agitation; new death in lecanemab trial raises concerns
By
Alicia Lasek
Nov 30, 2022
Two drugs in late-stage clinical trials are making news, one as a potential treatment for agitation, and the other for evidence of bleeding risk.
Trial begins of nasal vaccine for Alzheimer disease
Nov 18, 2021
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.